Details of Disease

General Information of Disease (ID: DISX61LX)

Disease Name Human papillomavirus infection
Synonyms Human papilloma Virus infection; Human Papillomavirus infection; Human papillomavirus infectious disease; Human papillomavirus caused disease or disorder; Human papillomavirus disease or disorder
Disease Class 1A9Y-1A9Z: Sexually transmitted infection
Definition An infectious process caused by a human papillomavirus. This infection can cause abnormal tissue growth.
Disease Hierarchy
DISDI77C: Primary viral infectious disease
DISEM33Q: Infectious disease
DISX61LX: Human papillomavirus infection
ICD Code
ICD-11
ICD-11: 1A9Y
ICD-9
ICD-9: 078.1079.4
Expand ICD-11
'1A9Y
Expand ICD-9
078.1079.4
Disease Identifiers
MONDO ID
MONDO_0005161
MESH ID
D030361
UMLS CUI
C0343641
MedGen ID
87475
SNOMED CT ID
240532009

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 2 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Cervarix DM9GNJJ Approved NA [1]
Gardasil DM6TF30 Approved Small molecular drug [1]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 19 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
HPV 16/18 vaccine DM2NUHZ Phase 3 NA [2]
V-503 DMO40KX Phase 3 NA [3]
VGX-3100 DMMQ2U9 Phase 3 NA [4]
Zarnestra DMF30HL Phase 3 Small molecular drug [5]
ADXS11-001 DMZV6DQ Phase 2 NA [6]
HPV-16 E7 vaccine DMLRV69 Phase 2 NA [7]
Interferon DMYTKF5 Phase 2 NA [8]
Procervix DMEVU3B Phase 2 NA [9]
PVX-2 DMVCU5N Phase 2 Vaccine [10]
Santalum DMM9KK9 Phase 2 NA [11]
TVGV-1 vaccine DMHD4NZ Phase 2 NA [12]
V505 DMH8649 Phase 2 NA [13]
DPX E7 DM8T7YP Phase 1/2 NA [12]
JNJ-63682918 DMXLILL Phase 1/2 Vaccine [14]
JNJ-63682931 DMYMA8G Phase 1/2 Vaccine [14]
JNJ-65195208 DMKKZ3Z Phase 1/2 Vaccine [14]
CIGB-228 DMJFPK6 Phase 1 Vaccine [15]
PDS-0101 DMOCWNT Phase 1 NA [12]
V502 DME8ZB5 Phase 1 Vaccine [16]
------------------------------------------------------------------------------------
⏷ Show the Full List of 19 Drug(s)
This Disease is Treated as An Indication in 5 Discontinued Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
BCG65-E7 DMAMFXC Discontinued in Phase 3 NA [17]
ISIS 2105 DMR2STB Discontinued in Phase 2 Antisense drug [18]
TA-GW DMOU7ZJ Discontinued in Phase 2 NA [19]
GNI-105 DMI1S34 Terminated NA [20]
Papillomavirus vaccine DM5BTII Terminated NA [21]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 4 Investigative Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
EG-HPV DMPUNFR Investigative NA [8]
RBT-201 DMAET79 Investigative NA [8]
STxB-E7 DMBOZV8 Investigative NA [8]
Vaginal ring DMT22PF Investigative NA [8]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 30 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
ANTXR2 TTOD34I Limited Biomarker [22]
CD83 TTT9MRQ Limited Biomarker [23]
DUT TTH6MBO Limited Biomarker [24]
FGFR4 TT1KX2S Limited Biomarker [25]
IL19 TT87RWS Limited Genetic Variation [26]
MFGE8 TT1GLAJ Limited Biomarker [27]
NCR1 TTQNRJM Limited Altered Expression [28]
RNASEL TT7V0K4 Limited Biomarker [29]
SERPIND1 TT8XSKJ Limited Genetic Variation [30]
TSG101 TTHU7JA Limited Biomarker [31]
TUSC2 TTJ8O14 Limited Genetic Variation [32]
CLCN3 TT8XNZ7 moderate Altered Expression [33]
GEM TTAZF9M moderate Biomarker [34]
PDXP TT9UYG4 moderate Biomarker [35]
APOBEC3G TTP96KH Strong Biomarker [36]
CASP8 TT6SZNG Strong Biomarker [37]
DEFB4A TTIVY12 Strong Biomarker [38]
FHIT TTMS54D Strong Posttranslational Modification [39]
FOSL2 TT689IR Strong Biomarker [40]
GHRHR TTG4R8V Strong Altered Expression [41]
GNAO1 TTAXD8Z Strong Biomarker [42]
HLA-DQB2 TTL7VOU Strong Biomarker [42]
HSP90B1 TTFPKXQ Strong Biomarker [43]
PGR TTUV8G9 Strong Biomarker [44]
PMEL TT8MK59 Strong Biomarker [45]
PSMB8 TTEAD9J Strong Biomarker [46]
REG3A TTL4H8N Strong Genetic Variation [32]
STS TTHM0R1 Strong Biomarker [47]
TDO2 TTXNCBV Strong Altered Expression [48]
ZAP70 TTUMHT8 Strong Biomarker [49]
------------------------------------------------------------------------------------
⏷ Show the Full List of 30 DTT(s)
This Disease Is Related to 2 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
SLC52A3 DTBVQIO Limited Biomarker [50]
SLC25A20 DTQOUM4 moderate Genetic Variation [51]
------------------------------------------------------------------------------------
This Disease Is Related to 5 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
ACP3 DEDW5H6 Limited Genetic Variation [32]
AKR1C1 DE7P2FB Limited Altered Expression [52]
GSTT1 DE3PKUG Strong Genetic Variation [53]
PGPEP1 DEVDR46 Strong Biomarker [54]
SULT2A1 DE0P6LK Strong Biomarker [49]
------------------------------------------------------------------------------------
This Disease Is Related to 83 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
AGA OTNWT1WB Limited Genetic Variation [55]
ANXA3 OTDD8OI7 Limited Biomarker [56]
APOBEC3A OTYO6F5P Limited Biomarker [57]
ASAP1 OT4DLRYY Limited Genetic Variation [32]
ASAP2 OTGEXULW Limited Genetic Variation [32]
B3GNT3 OTVT1Q25 Limited Altered Expression [58]
CEMIP OTK80FYN Limited Altered Expression [59]
CUL2 OTPF83PG Limited Altered Expression [60]
DCT OTYVNTBG Limited Biomarker [61]
DGCR8 OT62LXE4 Limited Altered Expression [62]
DHDH OTKA2AL6 Limited Altered Expression [52]
DNAJA4 OTT7YCD2 Limited Biomarker [63]
DOCK8 OTNQLL21 Limited Biomarker [64]
HSPB6 OTFPLGZI Limited Biomarker [65]
KIF20A OTXOQHE0 Limited Altered Expression [66]
KLRC2 OTT4N86S Limited Genetic Variation [67]
KLRD1 OTMYLOV4 Limited Genetic Variation [67]
LYPD5 OTGP7UKA Limited Altered Expression [68]
MARVELD2 OTKB96L5 Limited Biomarker [69]
MPG OTAHW80B Limited Biomarker [70]
MRPS30 OTDXIAGG Limited Genetic Variation [32]
MTPAP OT6HQ02S Limited Genetic Variation [32]
MYCBP2 OTHODA1F Limited Biomarker [71]
OR2AG1 OTEITRP4 Limited Biomarker [72]
PAPOLA OTPHD65D Limited Genetic Variation [32]
PDCD6IP OTS8T6A7 Limited Biomarker [73]
PEG3 OTHQW98S Limited Genetic Variation [74]
PISD OTP9COQT Limited Genetic Variation [75]
PLCE1 OTJISZOX Limited Genetic Variation [76]
POLI OTBA4DCE Limited Genetic Variation [77]
PPP1R14B OT9PTWAX Limited Biomarker [78]
PSMA1 OTNBVM2U Limited Genetic Variation [30]
RAB40B OTCA9ZF5 Limited Genetic Variation [79]
RBM25 OTVOUOAG Limited Biomarker [62]
RHBDL1 OTSCUCQV Limited Genetic Variation [80]
RINT1 OTMO19ZD Limited Biomarker [81]
RNPS1 OT7G4COD Limited Altered Expression [82]
RRBP1 OT4ZTPTM Limited Genetic Variation [80]
RRS1 OTTNCZN6 Limited Genetic Variation [83]
SDCBP OTS3NCC5 Limited Biomarker [73]
SEC14L2 OTJST64D Limited Genetic Variation [84]
SLPI OTUNFUU8 Limited Altered Expression [85]
SRSF2 OTVDHO6U Limited Altered Expression [82]
IFI16 OT4SPU0U Disputed Altered Expression [86]
FCGBP OT63T6XQ moderate Altered Expression [87]
KIR3DL1 OTPOSXFX moderate Biomarker [34]
MLH3 OT91PPBI moderate Genetic Variation [88]
REV1 OTHIKICX moderate Genetic Variation [89]
APOBEC3B OTHLNI51 Strong Genetic Variation [90]
ARRDC3 OTAKW7R9 Strong Biomarker [91]
BRMS1 OTV5A6LL Strong Posttranslational Modification [92]
CCNA1 OTX4HD45 Strong Biomarker [37]
CLSPN OTZZXNDK Strong Altered Expression [93]
DEFB1 OT5SV0E4 Strong Biomarker [38]
DEFB104A OTLQZR6K Strong Genetic Variation [94]
DPH1 OT0QU3JY Strong Altered Expression [95]
EVC2 OTY0M5SD Strong Biomarker [96]
FLG OTE9QDV6 Strong Genetic Variation [97]
FLNB OTPCOYL6 Strong Genetic Variation [84]
HLA-C OTV38BUJ Strong Genetic Variation [98]
INTS2 OT2N5TCK Strong Biomarker [99]
LIMD1 OTN1CG6R Strong Genetic Variation [100]
LPIN1 OTQ75KF2 Strong Biomarker [54]
METTL9 OT3YR9B2 Strong Biomarker [54]
MTREX OTSQY30V Strong Genetic Variation [101]
NXF1 OTEFHXG6 Strong Genetic Variation [84]
PAX1 OT0Y3MIM Strong Posttranslational Modification [102]
PDAP1 OTJSWMOD Strong Genetic Variation [32]
PLAA OTZ7NJGA Strong Biomarker [101]
PPIP5K1 OT06HYH8 Strong Genetic Variation [103]
PTTG1IP OTX21QTE Strong Altered Expression [104]
PYCARD OT67RON3 Strong Biomarker [47]
RBM45 OTWTHD77 Strong Biomarker [105]
RBMX2 OTGGU7N1 Strong Biomarker [106]
RHOH OT1J9SEB Strong Biomarker [107]
RP9 OTGQY66H Strong Biomarker [54]
SALL3 OTJ2LZKQ Strong Posttranslational Modification [108]
SH3GL2 OTOE443G Strong Genetic Variation [109]
SMG1 OTTS3SXE Strong Biomarker [110]
STIL OT9799VN Strong Biomarker [45]
TMC6 OTKH50J4 Strong Genetic Variation [111]
TMC8 OTUAD95X Strong Genetic Variation [112]
ATAD3A OTWF6HBP Definitive Altered Expression [113]
------------------------------------------------------------------------------------
⏷ Show the Full List of 83 DOT(s)

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 ClinicalTrials.gov (NCT01735006) Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent ype 16/18 accine. U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT00988884) A Study of V503 Given Concomitantly With Menactra and Adacel in 11 to 15 Year Olds (V503-005). U.S. National Institutes of Health.
4 ClinicalTrials.gov (NCT01304524) A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3. U.S. National Institutes of Health.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 ClinicalTrials.gov (NCT01266460) Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer. U.S. National Institutes of Health.
8 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
9 ClinicalTrials.gov (NCT01957878) Phase II Study of HPV Therapeutic Vaccine in HPV Infected Women With Normal Cytology or ASCUS/LSIL. U.S. National Institutes of Health.
10 ClinicalTrials.gov (NCT03911076) Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL (PVX-2). U.S. National Institutes of Health.
11 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
12 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
13 ClinicalTrials.gov (NCT00520598) Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001). U.S. National Institutes of Health.
14 ClinicalTrials.gov (NCT03610581) Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix. U.S. National Institutes of Health.
15 Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial. ISRN Obstet Gynecol. 2011; 2011: 292951.
16 ClinicalTrials.gov (NCT00851643) Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002). U.S. National Institutes of Health.
17 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009576)
18 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001932)
19 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008623)
20 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016469)
21 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018155)
22 Signal-amplified colorimetric in situ hybridization for assessment of human papillomavirus infection in cervical lesions.Mod Pathol. 2001 Jul;14(7):702-9. doi: 10.1038/modpathol.3880375.
23 Genetic variation in CD83 and risks of cervical and vulvar cancers: a population-based case-control study.Gynecol Oncol. 2012 Mar;124(3):525-8. doi: 10.1016/j.ygyno.2011.11.017. Epub 2011 Nov 28.
24 Genetic variants of the dUTPase-encoding gene DUT increase HR-HPV infection rate and cervical squamous cell carcinoma risk.Sci Rep. 2019 Jan 24;9(1):513. doi: 10.1038/s41598-018-36757-7.
25 Study on the Association between the Fibroblast Growth Factor Receptor 4 Expression and High-Risk Human Papillomavirus Infection in Cervical Cancer and Precancerous Lesions.Gynecol Obstet Invest. 2018;83(6):608-614. doi: 10.1159/000490562. Epub 2018 Jul 6.
26 IL-10 gene polymorphism c.-592C>A increases HPV infection susceptibility and influences IL-10 levels in HPV infected women.Infect Genet Evol. 2017 Sep;53:128-134. doi: 10.1016/j.meegid.2017.05.020. Epub 2017 May 25.
27 Quantitative proteomic analysis of milk fat globule membrane (MFGM) proteins from donkey colostrum and mature milk.Food Funct. 2019 Jul 17;10(7):4256-4268. doi: 10.1039/c9fo00386j.
28 Mechanistic investigation of immunosuppression in patients with condyloma acuminata.Mol Med Rep. 2013 Aug;8(2):480-6. doi: 10.3892/mmr.2013.1511. Epub 2013 Jun 6.
29 Germline mutation in RNASEL predicts increased risk of head and neck, uterine cervix and breast cancer.PLoS One. 2008 Jun 25;3(6):e2492. doi: 10.1371/journal.pone.0002492.
30 HPV test by Hybrid Capture II for the diagnosis of HR-HPV persistent infection.Med Mal Infect. 2017 Nov;47(7):484-489. doi: 10.1016/j.medmal.2017.05.013. Epub 2017 Sep 22.
31 Human papillomavirus infection requires the TSG101 component of the ESCRT machinery.Virology. 2014 Jul;460-461:83-90. doi: 10.1016/j.virol.2014.05.005. Epub 2014 May 29.
32 Prevalence of human papillomavirus infection in women in the Autonomous Region of Inner Mongolia: A population-based study of a Chinese ethnic minority.J Med Virol. 2018 Jan;90(1):148-156. doi: 10.1002/jmv.24888. Epub 2017 Oct 6.
33 Overexpression of chloride channel-3 (ClC-3) is associated with human cervical carcinoma development and prognosis.Cancer Cell Int. 2019 Jan 8;19:8. doi: 10.1186/s12935-018-0721-x. eCollection 2019.
34 Implication of HLA-C and KIR alleles in human papillomavirus infection and associated cervical lesions.Viral Immunol. 2014 Nov;27(9):468-70. doi: 10.1089/vim.2014.0017. Epub 2014 Sep 4.
35 The direct and indirect association of cervical microbiota with the risk of cervical intraepithelial neoplasia.Cancer Med. 2018 May;7(5):2172-2179. doi: 10.1002/cam4.1471. Epub 2018 Apr 2.
36 Correlation of APOBEC3G Polymorphism with Human Papillomavirus (HPV) Persistent Infection and Progression of Cervical Lesions.Med Sci Monit. 2019 Sep 17;25:6990-6997. doi: 10.12659/MSM.916142.
37 Comprehensive analysis of DNA methylation in head and neck squamous cell carcinoma indicates differences by survival and clinicopathologic characteristics.PLoS One. 2013;8(1):e54742. doi: 10.1371/journal.pone.0054742. Epub 2013 Jan 24.
38 Human beta-defensin 1, 2 and 3 production by amniotic epithelial cells with respect to human papillomavirus (HPV) infection, HPV oncogenic potential and the mode of delivery.Microb Pathog. 2016 Aug;97:154-65. doi: 10.1016/j.micpath.2016.06.010. Epub 2016 Jun 8.
39 Frequent epigenetic silencing of the FHIT gene in penile squamous cell carcinomas.Virchows Arch. 2008 Apr;452(4):377-82. doi: 10.1007/s00428-008-0597-6. Epub 2008 Feb 26.
40 Constitutive activation and overexpression of NF-B/c-Rel in conjunction with p50 contribute to aggressive tongue tumorigenesis.Oncotarget. 2018 Aug 31;9(68):33011-33029. doi: 10.18632/oncotarget.26041. eCollection 2018 Aug 31.
41 Prognostic role of HPV infection in esophageal squamous cell carcinoma.Infect Agent Cancer. 2018 Nov 29;13:38. doi: 10.1186/s13027-018-0210-9. eCollection 2018.
42 Association between the HLA DQB1*0301 gene and human papillomavirus infection in high-grade cervical intraepithelial neoplasia.Int J Gynecol Pathol. 1999 Jul;18(3):206-10. doi: 10.1097/00004347-199907000-00003.
43 Proteomic investigation in A549 lung cell line stably infected by HPV16E6/E7 oncogenes.Respiration. 2009;77(4):427-39. doi: 10.1159/000176209. Epub 2008 Nov 20.
44 Expression of Estrogen and Progesterone Receptor in Tumor Stroma Predicts Favorable Prognosis of Cervical Squamous Cell Carcinoma.Int J Gynecol Cancer. 2017 Jul;27(6):1247-1255. doi: 10.1097/IGC.0000000000001004.
45 Carcinogenic HPV infection in the cervical squamo-columnar junction.J Pathol. 2015 Jul;236(3):265-71. doi: 10.1002/path.4533. Epub 2015 Apr 27.
46 Genetic variability in LMP2 and LMP7 is associated with the risk of esophageal squamous cell carcinoma in the Kazakh population but is not associated with HPV infection.PLoS One. 2017 Oct 26;12(10):e0186319. doi: 10.1371/journal.pone.0186319. eCollection 2017.
47 Type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand.BMC Infect Dis. 2013 Mar 3;13:114. doi: 10.1186/1471-2334-13-114.
48 Indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase expression in HPV infection, SILs, and cervical cancer.Cancer Cytopathol. 2019 Sep;127(9):586-597. doi: 10.1002/cncy.22172. Epub 2019 Aug 14.
49 PCR-RFLP-detected human papilloma virus infection in a group of senegalese women attending an STD clinic and identification of a new HPV-68 subtype.Intervirology. 1999;42(4):221-7. doi: 10.1159/000024981.
50 Association of the plasma and tissue riboflavin levels with C20orf54 expression in cervical lesions and its relationship to HPV16 infection.PLoS One. 2013 Nov 18;8(11):e79937. doi: 10.1371/journal.pone.0079937. eCollection 2013.
51 Association of the MUTYH Gln324His (CAG/CAC) variant with cervical carcinoma and HR-HPV infection in a Chinese population.Medicine (Baltimore). 2019 Apr;98(17):e15359. doi: 10.1097/MD.0000000000015359.
52 Infection of human papillomavirus and overexpression of dihydrodiol dehydrogenase in uterine cervical cancer.Gynecol Oncol. 2006 Aug;102(2):173-81. doi: 10.1016/j.ygyno.2005.12.009. Epub 2006 Jan 20.
53 Polymorphic variants conferring genetic risk to cervical lesions support GSTs as important associated loci.Medicine (Baltimore). 2019 Oct;98(41):e17487. doi: 10.1097/MD.0000000000017487.
54 Detection of human papillomavirus DNA by the hybrid capture assay.Braz J Infect Dis. 2003 Apr;7(2):121-5. doi: 10.1590/s1413-86702003000200004. Epub 2003 Nov 19.
55 The nonsynonymous single-nucleotide polymorphisms in codon 31 of p21 gene and the susceptibility to cervical cancer in Chinese women.Int J Gynecol Cancer. 2009 Aug;19(6):1011-4. doi: 10.1111/IGC.0b013e3181a8b950.
56 Hybrid capture based human papillomavirus typing in cervical screening compared to cytology and histology.Wien Klin Wochenschr. 2000 Sep 15;112(17):761-6.
57 Roles of APOBEC3A and APOBEC3B in Human Papillomavirus Infection and Disease Progression.Viruses. 2017 Aug 21;9(8):233. doi: 10.3390/v9080233.
58 B3GNT3 Expression Is a Novel Marker Correlated with Pelvic Lymph Node Metastasis and Poor Clinical Outcome in Early-Stage Cervical Cancer.PLoS One. 2015 Dec 28;10(12):e0144360. doi: 10.1371/journal.pone.0144360. eCollection 2015.
59 NF-B-induced KIAA1199 promotes survival through EGFR signalling.Nat Commun. 2014 Nov 4;5:5232. doi: 10.1038/ncomms6232.
60 Human Papillomavirus 16 E7 Stabilizes APOBEC3A Protein by Inhibiting Cullin 2-Dependent Protein Degradation.J Virol. 2018 Mar 14;92(7):e01318-17. doi: 10.1128/JVI.01318-17. Print 2018 Apr 1.
61 The Role of DCT in HPV16 Infection of HaCaTs.PLoS One. 2017 Jan 17;12(1):e0170158. doi: 10.1371/journal.pone.0170158. eCollection 2017.
62 HPV shapes tumor transcriptome by globally modifying the pool of RNA binding protein-binding motif.Aging (Albany NY). 2019 Apr 29;11(8):2430-2446. doi: 10.18632/aging.101927.
63 DNAJA4 deficiency enhances NF-kappa B-related growth arrest induced by hyperthermia in human keratinocytes.J Dermatol Sci. 2018 Sep;91(3):256-267. doi: 10.1016/j.jdermsci.2018.05.006. Epub 2018 May 23.
64 Warts and all: human papillomavirus in primary immunodeficiencies.J Allergy Clin Immunol. 2012 Nov;130(5):1030-48. doi: 10.1016/j.jaci.2012.07.049. Epub 2012 Oct 1.
65 Significance of serum antibodies against HPV E7, Hsp27, Hsp20 and Hp91 in Iranian HPV-exposed women.BMC Infect Dis. 2019 Feb 12;19(1):142. doi: 10.1186/s12879-019-3780-2.
66 High Expression of KIF20A Is Associated with Poor Overall Survival and Tumor Progression in Early-Stage Cervical Squamous Cell Carcinoma.PLoS One. 2016 Dec 12;11(12):e0167449. doi: 10.1371/journal.pone.0167449. eCollection 2016.
67 Evaluation of the association of NKG2C copy number variations with susceptibility to human papillomavirus-induced cervical lesions.Hum Immunol. 2013 Oct;74(10):1352-6. doi: 10.1016/j.humimm.2013.07.006. Epub 2013 Jul 31.
68 MiR-30c-2* negative regulated MTA-1 expression involved in metastasis and drug resistance of HPV-infected non-small cell lung cancer.Surgery. 2016 Dec;160(6):1591-1598. doi: 10.1016/j.surg.2016.06.025. Epub 2016 Aug 6.
69 Altered expression of claudin-1, claudin-7, and tricellulin regardless of human papilloma virus infection in human tonsillar squamous cell carcinoma.Acta Otolaryngol. 2011 Aug;131(8):861-8. doi: 10.3109/00016489.2011.562537. Epub 2011 Apr 11.
70 Comparison of hybrid capture II, linear array, and a bead-based multiplex genotyping assay for detection of human papillomavirus in women with negative pap test results and atypical squamous cells of undetermined significance.J Clin Microbiol. 2012 Dec;50(12):4041-6. doi: 10.1128/JCM.02105-12. Epub 2012 Oct 3.
71 Association between the vaginal microbiome and high-risk human papillomavirus infection in pregnant Chinese women.BMC Infect Dis. 2019 Aug 1;19(1):677. doi: 10.1186/s12879-019-4279-6.
72 Inactivation of RAS association domain family 1A gene in cervical carcinomas and the role of human papillomavirus infection.Cancer Res. 2003 Apr 15;63(8):1888-93.
73 The CD63-Syntenin-1 Complex Controls Post-Endocytic Trafficking of Oncogenic Human Papillomaviruses.Sci Rep. 2016 Aug 31;6:32337. doi: 10.1038/srep32337.
74 Associations between methylation of paternally expressed gene 3 (PEG3), cervical intraepithelial neoplasia and invasive cervical cancer.PLoS One. 2013;8(2):e56325. doi: 10.1371/journal.pone.0056325. Epub 2013 Feb 13.
75 The retinoblastoma protein/p16 INK4A pathway but not p53 is disrupted by human papillomavirus in penile squamous cell carcinoma.Histopathology. 2011 Feb;58(3):433-9. doi: 10.1111/j.1365-2559.2011.03762.x. Epub 2011 Feb 16.
76 Heterozygote of PLCE1 rs2274223 increases susceptibility to human papillomavirus infection in patients with esophageal carcinoma among the Kazakh populations.J Med Virol. 2014 Apr;86(4):608-17. doi: 10.1002/jmv.23775. Epub 2013 Oct 11.
77 No association of the POLI Thr706Ala polymorphism with the risk of cervical carcinoma.Eur J Surg Oncol. 2008 Aug;34(8):916-920. doi: 10.1016/j.ejso.2007.11.008. Epub 2008 Jan 14.
78 Ambiguous bodies, uncertain diseases: knowledge of cervical cancer in Papua New Guinea.Ethn Health. 2018 Aug;23(6):659-681. doi: 10.1080/13557858.2017.1283393. Epub 2017 Feb 3.
79 Population-based case-control study on DAPK1, RAR-2 and MGMT methylation in liquid-based cytology.Arch Gynecol Obstet. 2012 May;285(5):1433-9. doi: 10.1007/s00404-011-2149-6. Epub 2011 Nov 25.
80 HPV genotyping and HLA II analysis in a pedigree study of pediatric RRP: preliminary results.Int J Pediatr Otorhinolaryngol. 2006 Nov;70(11):1935-9. doi: 10.1016/j.ijporl.2006.07.003. Epub 2006 Aug 21.
81 Association of Human Papillomavirus 16 E2 with Rad50-Interacting Protein 1 Enhances Viral DNA Replication.J Virol. 2017 Feb 14;91(5):e02305-16. doi: 10.1128/JVI.02305-16. Print 2017 Mar 1.
82 Human papillomavirus regulation of SR proteins.Biochem Soc Trans. 2010 Aug;38(4):1116-21. doi: 10.1042/BST0381116.
83 Prevalence of and Risk Factors for Oral Human Papillomavirus Infection With Multiple Genotypes in the United States.Sex Transm Dis. 2017 Mar;44(3):166-172. doi: 10.1097/OLQ.0000000000000563.
84 Association of TAP gene polymorphisms and risk of cervical intraepithelial neoplasia.Dis Markers. 2013;35(2):79-84. doi: 10.1155/2013/368732. Epub 2013 Jul 28.
85 Smoking-Induced SLPI Expression Hinders HPV Infections Also in Squamous Cell Carcinomas of the Vulva.Transl Oncol. 2019 Jan;12(1):36-42. doi: 10.1016/j.tranon.2018.09.004. Epub 2018 Sep 26.
86 PYHIN genes as potential biomarkers for prognosis of human papillomavirus-positive or -negative head and neck squamous cell carcinomas.Mol Biol Rep. 2019 Jun;46(3):3333-3347. doi: 10.1007/s11033-019-04795-7. Epub 2019 Apr 12.
87 FcGBP was upregulated by HPV infection and correlated to longer survival time of HNSCC patients.Oncotarget. 2017 Sep 23;8(49):86503-86514. doi: 10.18632/oncotarget.21220. eCollection 2017 Oct 17.
88 Mismatch repair gene MLH3 Pro844Leu and Thr942Ile polymorphisms and the susceptibility to cervical carcinoma and HPV infection: a case-control study in a Chinese population.PLoS One. 2014 Apr 23;9(4):e96224. doi: 10.1371/journal.pone.0096224. eCollection 2014.
89 REV1 genetic variants associated with the risk of cervical carcinoma.Eur J Epidemiol. 2008;23(6):403-9. doi: 10.1007/s10654-008-9251-5. Epub 2008 May 10.
90 Human Papillomavirus 16 E6 Upregulates APOBEC3B via the TEAD Transcription Factor.J Virol. 2017 Feb 28;91(6):e02413-16. doi: 10.1128/JVI.02413-16. Print 2017 Mar 15.
91 Genome-wide association study of cervical cancer suggests a role for ARRDC3 gene in human papillomavirus infection.Hum Mol Genet. 2019 Jan 15;28(2):341-348. doi: 10.1093/hmg/ddy390.
92 Gene promoter methylation and protein expression of BRMS1 in uterine cervix in relation to high-risk human papilloma virus infection and cancer.Tumour Biol. 2017 Apr;39(4):1010428317697557. doi: 10.1177/1010428317697557.
93 Claspin as a biomarker of human papillomavirus-related high grade lesions of uterine cervix.J Transl Med. 2012 Jun 25;10:132. doi: 10.1186/1479-5876-10-132.
94 Copy number variation of the antimicrobial-gene, defensin beta 4, is associated with susceptibility to cervical cancer.J Hum Genet. 2013 May;58(5):250-3. doi: 10.1038/jhg.2013.7. Epub 2013 Mar 7.
95 OVCA1 expression and its correlation with the expression levels of cyclin D1 and p16 in cervical cancer and intraepithelial neoplasia.Oncol Lett. 2017 May;13(5):2929-2936. doi: 10.3892/ol.2017.5848. Epub 2017 Mar 13.
96 Infection and HLA-G molecules in nasal polyposis.J Immunol Res. 2014;2014:407430. doi: 10.1155/2014/407430. Epub 2014 Mar 6.
97 Common filaggrin gene mutations and risk of cervical cancer.Acta Oncol. 2015 Feb;54(2):217-23. doi: 10.3109/0284186X.2014.973613. Epub 2014 Nov 10.
98 HLA-C -35kb expression SNP is associated with differential control of -HPV infection in squamous cell carcinoma cases and controls.PLoS One. 2014 Aug 1;9(8):e103710. doi: 10.1371/journal.pone.0103710. eCollection 2014.
99 First hints for a correlation between amplification of the Int-2 gene and infection with human papillomavirus in head and neck squamous cell carcinomas.J Oral Pathol Med. 2000 Oct;29(9):432-7. doi: 10.1034/j.1600-0714.2000.290903.x.
100 LIMD1 is more frequently altered than RB1 in head and neck squamous cell carcinoma: clinical and prognostic implications.Mol Cancer. 2010 Mar 12;9:58. doi: 10.1186/1476-4598-9-58.
101 HLA DOA1 and DOB1 loci in Honduran women with cervical dysplasia and invasive cervical carcinoma and their relationship to human papillomavirus infection.Hum Biol. 1999 Jun;71(3):367-79.
102 Association between dense PAX1 promoter methylation and HPV16 infection in cervical squamous epithelial neoplasms of Xin Jiang Uyghur and Han women.Gene. 2020 Jan 10;723:144142. doi: 10.1016/j.gene.2019.144142. Epub 2019 Oct 4.
103 Decline in prevalence of human papillomavirus infection following vaccination among Australian Indigenous women, a population at higher risk of cervical cancer: The VIP-I study.Vaccine. 2018 Jul 5;36(29):4311-4316. doi: 10.1016/j.vaccine.2018.05.104. Epub 2018 Jun 5.
104 PTTG and PBF Functionally Interact with p53 and Predict Overall Survival in Head and Neck Cancer.Cancer Res. 2018 Oct 15;78(20):5863-5876. doi: 10.1158/0008-5472.CAN-18-0855. Epub 2018 Aug 28.
105 Variations in immunogenetics, human papillomavirus (HPV) infection & predisposition to cervical cancer in Indian women.Indian J Med Res. 2014 Nov;140 Suppl(Suppl 1):S36-43.
106 Enhanced specificity of the p53 family proteins-based adenoviral gene therapy in uterine cervical cancer cells with E2F1-responsive promoters.Cancer Biol Ther. 2006 Nov;5(11):1502-10. doi: 10.4161/cbt.5.11.3300. Epub 2006 Nov 19.
107 Inherited MST1 deficiency underlies susceptibility to EV-HPV infections.PLoS One. 2012;7(8):e44010. doi: 10.1371/journal.pone.0044010. Epub 2012 Aug 27.
108 Aberrant Hypermethylation of SALL3 with HPV Involvement Contributes to the Carcinogenesis of Cervical Cancer.PLoS One. 2015 Dec 23;10(12):e0145700. doi: 10.1371/journal.pone.0145700. eCollection 2015.
109 Aberrant promoter methylation of SH3GL2 gene in vulvar squamous cell carcinoma correlates with clinicopathological characteristics and HPV infection status.Int J Clin Exp Pathol. 2015 Nov 1;8(11):15442-7. eCollection 2015.
110 Downregulation of SMG-1 in HPV-positive head and neck squamous cell carcinoma due to promoter hypermethylation correlates with improved survival.Clin Cancer Res. 2012 Mar 1;18(5):1257-67. doi: 10.1158/1078-0432.CCR-11-2058. Epub 2012 Jan 13.
111 Variants of EVER1 and EVER2 (TMC6 and TMC8) and human papillomavirus status in patients with mucosal squamous cell carcinoma of the head and neck.Cancer Causes Control. 2016 Jun;27(6):809-15. doi: 10.1007/s10552-016-0749-y. Epub 2016 Apr 20.
112 Novel TMC8 splice site mutation in epidermodysplasia verruciformis and review of HPV infections in patients with the disease.J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1722-1726. doi: 10.1111/jdv.14431. Epub 2017 Aug 4.
113 Human papillomavirus infection and expression of ATPase family AAA domain containing 3A, a novel anti-autophagy factor, in uterine cervical cancer.Int J Mol Med. 2011 Nov;28(5):689-96. doi: 10.3892/ijmm.2011.743. Epub 2011 Jul 8.